Related Experiment Video
Updated: Apr 6, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Effects of add-on tipepidine on treatment-resistant depression: an open-label pilot trial
Yukihiko Shirayama1, Masatoshi Suzuki1, Michio Takahashi1
11Department of Psychiatry,Teikyo University Chiba Medical Center,Ichihara,Japan.
Objective:
Treatment-resistant depression is a challenging problem in the clinical setting. Tipepidine has been used as a non-narcotic antitussive in Japan since 1959.
Methods:
We administered tipepidine to 11 patients with treatment-resistant depression. Tipepidine was given for 8 weeks as an augmentation.
Results:
Tipepidine significantly improved depression scores on the Hamilton Rating Scale for depression. Add-on treatment with tipepidine significantly improved scores on the trail making test and Rey auditory verbal learning test. However, no changes were observed in blood concentrations of stress-related hormones (adrenocorticotropic hormone, cortisol, dehydroepiandrosterone sulphate) with tipepidine augmentation.
Conclusion:
Tipepidine might be a potential therapeutic drug for treatment-resistant depression.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Electroconvulsive Therapy
Desensitization and Tachyphylaxis
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

